By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login

Alumis Inc. Common Stock (ALMS)

NASDAQ Currency in USD
$4.36
+$0.06
+1.40%
Last Update: 11 Sept 2025, 20:00
$453.75M
Market Cap
-0.96
P/E Ratio (TTM)
Forward Dividend Yield
$2.76 - $13.11
52 Week Range

ALMS Stock Price Chart

Explore Alumis Inc. Common Stock interactive price chart. Choose custom timeframes to analyze ALMS price movements and trends.

ALMS Company Profile

Discover essential business fundamentals and corporate details for Alumis Inc. Common Stock (ALMS) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

22 Feb 2021

Employees

168.00

CEO

Martin Babler

Description

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

ALMS Financial Timeline

Browse a chronological timeline of Alumis Inc. Common Stock corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 12 May 2026

Upcoming earnings on 12 Nov 2025

EPS estimate is -$0.92, while revenue estimate is $3.14M.

Earnings released on 13 Aug 2025

EPS came in at -$1.17 falling short of the estimated -$1.11 by -5.41%, while revenue for the quarter reached $2.67M , missing expectations by -15.17%.

Earnings released on 14 May 2025

EPS came in at -$1.82 falling short of the estimated -$1.47 by -23.81%, while revenue for the quarter reached $17.39M , beating expectations by +943.34%.

Earnings released on 19 Mar 2025

EPS came in at -$0.23 surpassing the estimated -$1.40 by +83.57%, while revenue for the quarter reached $1.52M , beating expectations by +51.80%.

Earnings released on 13 Nov 2024

EPS came in at -$1.73 falling short of the estimated -$1.64 by -5.49%.

Earnings released on 13 Aug 2024

EPS came in at -$23.10 falling short of the estimated -$4.50 by -413.33%.

Earnings released on 31 Mar 2024

EPS came in at -$0.96 .

Earnings released on 31 Dec 2023

EPS came in at -$4.50 .

Earnings released on 30 Sept 2023

EPS came in at -$1.13 .

Earnings released on 29 Jun 2023

EPS came in at -$0.70 .

Earnings released on 31 Mar 2023

EPS came in at -$0.69 .

ALMS Stock Performance

Access detailed ALMS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run